Best Life Sciences Platforms and Tools Companies in Pennsylvania, United States

ChromaTan has developed Continuous Countercurrent Tangential Chromatography (CCTC) - a new column-free and single-use process that provides a cost-saving and scalable alternative to column chromatography. The company's CCTC platform has received technology endorsement from MedImmune/AstraZeneca, Regeneron, and NRC Canada. The company received a $2.5 Million contract from the FDA in September 2017 for developing a novel continuous purification platform for single-use and continuous bio-manufacturing.

Developer of AI-based platform for lab-grown human tissues. The company's platform culture human tissue models for drug discovery and utilizes single-cell 4D phenomics with an integrated confocal microscope. Also, has an automated robotic system that discovers drugs and cellular therapies.

Funding rounds

• Feb 2025Series A$77.7M
• Nov 2023Seed$38M
• Mar 2021Seed$2M

Founders & team

Dan HuhCo-FounderSheila AhernSenior Executive Assistant to Chief Executive Officer & C-Suite

Investors

Khosla Ventures, Kairos Ventures, CS Ventures, MBX Capital, Bison Ventures, Lingotto

Tech stack

Accessible360CdnjsCloudflareGoogle AnalyticsGoogle Tag ManagerGoogle Workspace

Antibody discovery and optimization platform impacting human disease research, diagnosis, and treatment. The company is a biopharmaceutical discovery and service provider specializing in modular antibody discovery and conditionally-active antibody engineering for immunotherapy. They utilize proprietary antibody generation and optimization platforms. Their unique eukaryotic in vitro antibody discovery/optimization platform is based on yeast-display, self-diversifying libraries, and rapid target-directed antibody affinity maturation combined with FACS single-cell sorting. The modular antibody discovery platform incorporates real-time screening for key properties like epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity, and target-specificity. They focus on therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation, and central nervous system disorders. This innovative approach enables the development of novel antibody therapeutics and diagnostics.

Medical technology product design and development for clinical translation. The company specializes in bringing medical technologies from concept to clinical application. They adhere to stringent FDA design controls and ISO standards, ensuring high-quality and regulatory compliance. Their core competencies lie in product design, development, and blood compatibility testing. They offer services related to medical devices, focusing on the clinical translation aspect. This indicates a business-to-business (B2B) model, providing specialized services to medical technology companies. They are not a software or SaaS company, but a product design and development firm within the medical technology sector.

Funding rounds

• Jan 2025Grant (prize money)$870.5K
• Feb 2017Grant (prize money)$299.8K
• Aug 2016Grant (prize money)$3.3M
• May 2015Grant (prize money)$225K

Founders & team

Philip LitwakFounderMark GartnerFounder

Investors

HHS

Provider of probes for atomic force microscopy (AFM) applications. It offers hard conductive coating such as a metal diboride film on probes and then the sharpening process to a radius-of-curvature of under 5 nm allows users to obtain AFM images over long periods of use.

Funding rounds

• Mar 2025Grant (prize money)$206.5K
• Sep 2024Grant (prize money)$275K
• Jul 2024Grant (prize money)$206.5K
• Apr 2018Grant (prize money)$2.4M

Founders & team

Scott LockledgeCo-Founder & CEOJoseph LydingCo-Founder & CTOGregory GirolamiCo-Founder & CSO

Investors

OSTI, National Science Foundation

Provider of a solution for isolating and analyzing extracellular vesicles. It focuses on cancer research and clinical management, specializing in the isolation and analysis of extracellular vesicles which carry valuable molecular information about diseases like cancer.

Funding rounds

• Mar 2025Grant (prize money)$1.1M
• Sep 2023Grant (prize money)$306.5K
• Jun 2023Grant (prize money)$400K
• Aug 2019Grant (prize money)$357K

Founders & team

HongZhang HECo-Founder & CEO

Investors

HHS

Life science company providing innovative tools for ubiquitin proteasome system research. They are dedicated to advancing research through cutting-edge technologies and comprehensive solutions. They offer a wide array of products and services focused on protein degradation pathways, including PROTACs, molecular glues, TUBEs, ubiquitin ligases, deubiquitinating enzymes, and SUMOylation tools. Their offerings span from reagents and assays to custom solutions, supporting drug discovery and basic research. They provide tools for ubiquitination, protein expression, and analysis, catering to diverse research needs in areas like neurodegeneration, cancer, and therapeutic development. They also offer R&D services, including PROTAC development, DUB assays, and mass spectrometry proteomics. They are committed to enabling scientific breakthroughs through their innovative products and expert support.

Developer of immunotherapies for a wide of diseases. The company's FANA RNA silencing platform is centered around 2'Fluoridated Arabinonucleic Acids, which can be used to synthesize oligonucleotides that can efficiently and persistently silence target gene activity. The company is focusing on developing antisense therapeutics based on the FANA platform in the broad areas of Hematology, Oncology, CNS, Kidney, Liver, IBD, GI, autoimmune and inflammatory diseases, cardiovascular diseases, as well as orphan diseases like DMD. The company is also looking at applying its technology to address challenges in agriculture and is collaborating with the USDA to develop non-GMO RNA silencing mediated crop traits against citrus greening for bacteria, insect, and pathogen control.

Developing targeted immunotherapy therapies by harnessing antigen-presenting cells. The company is dedicated to pioneering innovative approaches in immunotherapy research and development. They are focused on creating next-generation therapies. Their work involves laboratory research aimed at developing effective and targeted treatments. The company is involved in the biotechnology and pharmaceutical sectors, specifically focusing on cutting-edge medical solutions. They are working to advance healthcare through scientific discovery and therapeutic innovation. The company is committed to advancing the field of immunotherapy and improving patient outcomes through targeted therapeutic interventions. They are focused on research and development, aiming to create a positive social impact through advancements in medical science.

Funding rounds

• Sep 2024Grant (prize money)$306.5K
• Jul 2024Grant (prize money)$306.5K
• Dec 2012Grant (prize money)$256.2K

Founders & team

Larry ZanaCo-Founder & CEOSam RothsteinCo-Founder & CSO

Investors

HHS, Pittsburgh Life Sciences Greenhouse

Tech stack

BootstrapGoogle CloudGoogle Cloud CdnGoogle WorkspaceGsapHsts

MOBILion Systems offers analytical mass spectrometry instruments for diagnostic and therapeutic applications in clinical settings. The company has developed SLIM (Structures for Lossless Ion Manipulation) used for lossless ion transfer, manipulation, and ion mobility separations. Its applications include rapid biological sample analysis and biomolecule separation with high sensitivity and resolution.

Purolite is a manufacturer of quality ion exchange, catalyst, adsorbent and specialty high-performance resins. The company's products find critical applications in a wide range of industries including metallurgy, water purification, power, semiconductor, food and pharmaceuticals.

Funding rounds

• Jun 2020Conventional Debt$225M
• Apr 2020Conventional Debt$281.2M
• Sep 2009PE$135M
• Conventional Debt$75M

Founders & team

Christophe BeckCEO

Investors

HSBC, Santander Bank, PNC, Kfw-Ipex-Bank

Tech stack

Amazon CloudfrontAmazon Web ServicesApache Http ServerBootstrapCloudflareCloudflare Bot Management

Aprecia Pharmaceuticals develops and manufactures orodispersible tablets with a focus on high-dose medications using ZipDose Technology. ZipDose Technology utilizes its proprietary three-dimensional printing (3DP) platform. This process stitches together multiple layers of powdered medication using an aqueous fluid to produce a porous, water-soluble matrix that rapidly disintegrates with a sip of liquid. FDA has recently approved SPRITAM levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. SPRITAM utilizes its proprietary ZipDose Technology platform to produce a porous formulation that rapidly disintegrates with a sip of liquid. It plans to introduce multiple new products utilizing ZipDose Technology, focusing first on the central nervous system therapeutic area.

Funding rounds

• Jul 2016Venture Debt$20M
• Jan 2016Series D$79M
• Aug 2015Series D$38.8M
• Dec 2013Series C$14.9M

Founders & team

Owen MurrayCEO

Investors

Deerfield, Hercules Capital, Blue Chip Venture, Ben Franklin Technology Partners

Tech stack

Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesEwww Image OptimizerGauges